Postgraduate Course at DDW: Complete Clinical Updates for Today's Practice

Sun 15_Shaheen Barretts wish

Pdf Summary

Dr. Nicholas J. Shaheen's presentation at the University of North Carolina focuses on advancements and challenges in the management of Barrett’s Esophagus (BE) as of 2025. Key points include the emergence of non-endoscopic screening methods and tools for risk stratification, such as Wide Area Transepithelial Sampling (WATS) and AI imaging. These innovations aim to enhance diagnosis and screening efficiency for patients with BE.<br /><br />Dr. Shaheen discusses the importance of understanding the diverse results that might arise from adjunct diagnostic tests. For instance, a case study presented highlights the potential discrepancy between traditional biopsies and WATS 3D sampling results, which can show low-grade dysplasia (LGD) where none was previously detected. This indicates a need for clinicians to familiarize themselves with these technologies and their implications on patient management.<br /><br />The presentation also explores the utility and limitations of endoscopic surveillance. The BOSS trial is highlighted, demonstrating the potential lack of efficacy of regular surveillance. Despite limitations, such as significant endoscopy use even in "on-demand" groups, these findings contribute to the ongoing debate about the best management practices for BE.<br /><br />Quality measures like the Neoplasia Detection Rate (NDR) and Post-Endoscopy Esophageal Cancer Rate (PEEC) are introduced. These metrics might be increasingly relevant in clinical practice, guiding the quality of care provided to BE patients.<br /><br />Emerging treatments in the ablation market are also noted, suggesting possible improvements in therapeutic approaches to BE. The conclusion stresses the need for further research, including direct comparisons of diagnostic and treatment methods, to optimize patient outcomes. Overall, the presentation underscores a dynamic landscape in BE management, driven by technological advancements and evolving evidence.

Keywords

Barrett's Esophagus

non-endoscopic screening

risk stratification

Wide Area Transepithelial Sampling

AI imaging

endoscopic surveillance

BOSS trial

Neoplasia Detection Rate

Post-Endoscopy Esophageal Cancer Rate

ablation treatments